REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Amid a solid earnings picture for the second quarter, many US-listed companies are beating their estimates. Combining the ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 ...

An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related ...

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea ...